Gapping down
In reaction to disappointing earnings/guidance: VOXX -21.5% (also downgraded to Neutral from Buy at B. Riley & Co), RGSE -14.7%, XONE -13.4%, NTES -7.8%, WX -6.3%, PT -6.1%, SEAS -3.5%, KSS -3.4%, WMT -3.2%, DANG -2.9%, JACK -2.8%, A -1.5%, USU -1.1%, (USEC Inc. reports large Q1 net loss -- Chapter 11 process continues; co anticipates emerging this summer).
M&A news: BSX -0.4% (announces definitive agreement to acquire interventional division of Bayer AG for $415 mln in cash), AAPL -0.2% (acquisition of Beats has been moved back by 7 days, according to reports).
Other news: LIQD -30.4% (thinly traded, still checking on catalyst), SRNE -17.9% (prices 4,765,000 shares of common stock at a public offering price of $5.25 per share), NBG -13.3% (still checking), INCY -8.8% ( following release of ASCO abstracts; Presents data from two trials involving ruxolitinib), AMRN -7.9% (announces private exchange transactions regarding outstanding Senior Exchangeable Notes), SIR -5.2% (announces proposed public offering of 8 mln common shares ), DCIX -5.1% (still checking), SIR -4.9% (prices 9 mln shares of common stock at $29.00 per share), DK -1.9% (prices 9.2 mln shares of its common stock offered by Delek Hungary y (the Selling Stockholder) at $30.00 per share), ALU -1.5% (still checking), DDD -0.9% and SSYS -0.5% (following XONE results), PCYC -0.6% ( highlights new data for IMBRUVICA (ibrutinib) in B-cell malignancies).
Analyst comments: MTGE -1.6% (downgraded to Mkt Perform from Mkt Outperform at JMP Securities), VOD -1.3% ( downgraded to Neutral from Buy at Goldman ), ITC -1.1% (ITC Holdings downgraded to Neutral from Overweight at JPMorgan), BMY -0.2% (downgraded to Mkt Perform from Outperform at BMO Capital Mkts ), O -0.1% ( downgraded to Neutral from Buy at Ladenburg Thalmann)
M&A news: BSX -0.4% (announces definitive agreement to acquire interventional division of Bayer AG for $415 mln in cash), AAPL -0.2% (acquisition of Beats has been moved back by 7 days, according to reports).
Other news: LIQD -30.4% (thinly traded, still checking on catalyst), SRNE -17.9% (prices 4,765,000 shares of common stock at a public offering price of $5.25 per share), NBG -13.3% (still checking), INCY -8.8% ( following release of ASCO abstracts; Presents data from two trials involving ruxolitinib), AMRN -7.9% (announces private exchange transactions regarding outstanding Senior Exchangeable Notes), SIR -5.2% (announces proposed public offering of 8 mln common shares ), DCIX -5.1% (still checking), SIR -4.9% (prices 9 mln shares of common stock at $29.00 per share), DK -1.9% (prices 9.2 mln shares of its common stock offered by Delek Hungary y (the Selling Stockholder) at $30.00 per share), ALU -1.5% (still checking), DDD -0.9% and SSYS -0.5% (following XONE results), PCYC -0.6% ( highlights new data for IMBRUVICA (ibrutinib) in B-cell malignancies).
Analyst comments: MTGE -1.6% (downgraded to Mkt Perform from Mkt Outperform at JMP Securities), VOD -1.3% ( downgraded to Neutral from Buy at Goldman ), ITC -1.1% (ITC Holdings downgraded to Neutral from Overweight at JPMorgan), BMY -0.2% (downgraded to Mkt Perform from Outperform at BMO Capital Mkts ), O -0.1% ( downgraded to Neutral from Buy at Ladenburg Thalmann)